Quarterly ResultMay 14, 2026, 04:33 PM
Oncolytics Biotech Q1 Net Loss Widens to $9.24M; Going Concern Doubt
AI Summary
Oncolytics Biotech reported a widened net loss of $9.24 million for Q1 2026, compared to $4.71 million in Q1 2025, driven by increased operating expenses. The company also disclosed substantial doubt about its ability to continue as a going concern, as current cash resources are insufficient to fund operations for the next twelve months. To address liquidity, the company utilized an at-the-market offering, raising $7.61 million in net proceeds during the quarter, and entered into a new ATM agreement post-period.
Key Highlights
- Net loss widened to $9.24 million in Q1 2026 from $4.71 million in Q1 2025.
- Substantial doubt raised about the company's ability to continue as a going concern.
- Operating expenses increased to $9.28 million in Q1 2026 from $5.02 million in Q1 2025.
- Research and development expenses rose to $4.55 million from $2.80 million year-over-year.
- General and administrative expenses increased to $4.73 million from $2.22 million year-over-year.
- Net cash provided by financing activities was $7.61 million in Q1 2026, primarily from ATM offerings.
- Cash and cash equivalents stood at $5.49 million as of March 31, 2026.
- Functional currency changed to USD, reclassifying certain stock options as liabilities.